9M 2023 Financial Performance
9M 2023: R&D update
Anti-CD40L first neuroimmunology
program progressing
Mechanism of action for anti-CD40L (Lu AG22515)
24
B cell
Anti-CD40L scFv
Anti-Serum albumin Fab (SAFA)
Addressing immune-mediated
nervous system disorders
Differentiated anti-CD40L antibody-like drug
candidate
Recombinant bispecific scFv-Fab fusion
protein, binding to human serum albumin
Long half-life and expected improved safety
profile due to SAFA technology
CD40
CD40L
T cell
Cell expressing
FcRn
FcRn
Serum albumin (in blood)
Clinical development phase
Clinical development program initiated in
March 2022
Planned to progress to phase II in 2024 with
several potential neuro-immune indications
CD40L: cluster of differentiation 40 ligand, scFv: single-chain variable fragments, Fab: fragment, antigen-binding region
FcRn: neonatal crystallizable fragment receptorView entire presentation